Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding.
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics*; D015153:Blotting, Western; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D004983:Ethanolamines / Q000493:pharmacokinetics*; D016166:Free Radical Scavengers / Q000378:metabolism; D006801:Humans; D006900:Hydroxylation; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000378:metabolism; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism; D009249:NADP / Q000378:metabolism; D011485:Protein Binding; D017382:Reactive Oxygen Species / Q000378:metabolism; D011994:Recombinant Proteins; D013696:Temperature
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D016166:Free Radical Scavengers; D007527:Isoenzymes; D017382:Reactive Oxygen Species; D011994:Recombinant Proteins; D009249:NADP; C010831:bufuralol; D019389:Cytochrome P-450 CYP2D6